182 related articles for article (PubMed ID: 25644671)
1. Synthesis and anticancer activities of ceritinib analogs modified in the terminal piperidine ring.
Wang P; Cai J; Chen J; Ji M
Eur J Med Chem; 2015 Mar; 93():1-8. PubMed ID: 25644671
[TBL] [Abstract][Full Text] [Related]
2. Minor modifications to ceritinib enhance anti-tumor activity in EML4-ALK positive cancer.
Kang CH; Kim EY; Kim HR; Lee CO; Lee HK; Jeong HG; Choi SU; Yun CS; Hwang JY; Lee JY; Son YH; Ahn S; Lee BH; Jung H; Park CH
Cancer Lett; 2016 May; 374(2):272-8. PubMed ID: 26923554
[TBL] [Abstract][Full Text] [Related]
3. New palbociclib analogues modified at the terminal piperazine ring and their anticancer activities.
Wang P; Huang J; Wang K; Gu Y
Eur J Med Chem; 2016 Oct; 122():546-556. PubMed ID: 27448913
[TBL] [Abstract][Full Text] [Related]
4. Synthesis of novel thiazolyl-pyrimidines and their anticancer activity in vitro.
Shi HB; Li HB; Lu KQ; Zhu XR; Hu WX; Pei W
Arch Pharm (Weinheim); 2011 Oct; 344(10):675-83. PubMed ID: 21984017
[TBL] [Abstract][Full Text] [Related]
5. Discovery of a PROTAC targeting ALK with in vivo activity.
Yan G; Zhong X; Yue L; Pu C; Shan H; Lan S; Zhou M; Hou X; Yang J; Li R
Eur J Med Chem; 2021 Feb; 212():113150. PubMed ID: 33453602
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and biological evaluation of pazopanib derivatives as antitumor agents.
Jia Y; Zhang J; Feng J; Xu F; Pan H; Xu W
Chem Biol Drug Des; 2014 Mar; 83(3):306-16. PubMed ID: 24119291
[TBL] [Abstract][Full Text] [Related]
7. Synthesis, in vitro biological activities and in silico study of dihydropyrimidines derivatives.
Barakat A; Islam MS; Al-Majid AM; Ghabbour HA; Fun HK; Javed K; Imad R; Yousuf S; Choudhary MI; Wadood A
Bioorg Med Chem; 2015 Oct; 23(20):6740-8. PubMed ID: 26381063
[TBL] [Abstract][Full Text] [Related]
8. Synthesis, anticancer activity and effects on cell cycle profile and apoptosis of novel thieno[2,3-d]pyrimidine and thieno[3,2-e] triazolo[4,3-c]pyrimidine derivatives.
Kandeel MM; Refaat HM; Kassab AE; Shahin IG; Abdelghany TM
Eur J Med Chem; 2015 Jan; 90():620-32. PubMed ID: 25499930
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and anticancer activity of new monastrol analogues bearing 1,3,4-oxadiazole moiety.
Ragab FAF; Abou-Seri SM; Abdel-Aziz SA; Alfayomy AM; Aboelmagd M
Eur J Med Chem; 2017 Sep; 138():140-151. PubMed ID: 28667871
[TBL] [Abstract][Full Text] [Related]
10. Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors.
Achary R; Yun JI; Park CM; Mathi GR; Lee JY; Ha JD; Chae CH; Ahn S; Park CH; Lee CO; Hwang JY; Yun CS; Jung HJ; Cho SY; Kim HR; Kim P
Bioorg Med Chem; 2016 Jan; 24(2):207-19. PubMed ID: 26712094
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and docking studies of novel thienopyrimidine derivatives bearing chromone moiety as mTOR/PI3Kα inhibitors.
Zhu W; Chen C; Sun C; Xu S; Wu C; Lei F; Xia H; Tu Q; Zheng P
Eur J Med Chem; 2015 Mar; 93():64-73. PubMed ID: 25659752
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, anticancer activity and docking studies of novel 4-morpholino-7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidine derivatives as mTOR inhibitors.
Zhu W; Sun C; Xu S; Wu C; Wu J; Xu M; Zhao H; Chen L; Zeng W; Zheng P
Bioorg Med Chem; 2014 Dec; 22(24):6746-54. PubMed ID: 25468038
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and anti-tumor activities of some new pyridines and pyrazolo[1,5-a]pyrimidines.
Ahmed OM; Mohamed MA; Ahmed RR; Ahmed SA
Eur J Med Chem; 2009 Sep; 44(9):3519-23. PubMed ID: 19398146
[TBL] [Abstract][Full Text] [Related]
14. Anticancer activities of some newly synthesized pyrazole and pyrimidine derivatives.
Mohamed AM; El-Sayed WA; Alsharari MA; Al-Qalawi HR; Germoush MO
Arch Pharm Res; 2013 Sep; 36(9):1055-65. PubMed ID: 23737106
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and in vitro antiproliferative activity of novel Dasatinib derivatives.
Cai J; Zhang S; Zheng M; Wu X; Chen J; Ji M
Bioorg Med Chem Lett; 2012 Jan; 22(2):806-10. PubMed ID: 22217877
[TBL] [Abstract][Full Text] [Related]
16. Targeting Cysteine Located Outside the Active Site: An Effective Strategy for Covalent ALKi Design.
Yan G; Zhong X; Pu C; Yue L; Shan H; Lan S; Zhou M; Hou X; Yang J; Li D; Fan S; Li R
J Med Chem; 2021 Feb; 64(3):1558-1569. PubMed ID: 33471528
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, and biological evaluation of 2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidinyl derivatives as new irreversible epidermal growth factor receptor inhibitors with improved pharmacokinetic properties.
Xu S; Xu T; Zhang L; Zhang Z; Luo J; Liu Y; Lu X; Tu Z; Ren X; Ding K
J Med Chem; 2013 Nov; 56(21):8803-13. PubMed ID: 24124898
[TBL] [Abstract][Full Text] [Related]
18. Pyrroformyl-containing 2,4-diaminopyrimidine derivatives as a new optimization strategy of ALK inhibitors combating mutations.
Cao M; Chen Y; Zhao T; Wei S; Guo M; Zhai X
Bioorg Med Chem; 2020 Oct; 28(20):115715. PubMed ID: 33069079
[TBL] [Abstract][Full Text] [Related]
19. Structure-activity relationship study of arylsulfonylimidazolidinones as anticancer agents.
Sharma VK; Lee KC; Venkateswararao E; Joo C; Kim MS; Sharma N; Jung SH
Bioorg Med Chem Lett; 2011 Nov; 21(22):6829-32. PubMed ID: 21983438
[TBL] [Abstract][Full Text] [Related]
20. Design and synthesis of novel 1,2,3-triazole-pyrimidine-urea hybrids as potential anticancer agents.
Ma LY; Wang B; Pang LP; Zhang M; Wang SQ; Zheng YC; Shao KP; Xue DQ; Liu HM
Bioorg Med Chem Lett; 2015 Mar; 25(5):1124-8. PubMed ID: 25655718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
